Andrea Alfonso

how do we think about your gross margin improvement stacking versus that 30 to 80 bps

are you able to frame at all sort of how that sort of thinking in terms of just general cutoff points as far as age and frequency, where there's sort of agreeing on a sweet spot

the 2% to 5% revenue growth outlook constant currency does not include any benefit from Neogen

how do you think about that trajectory and sort of frame the levers that you have at your disposal

does that sort of delay negate kind of the $30,000,000-plus that you saw in 4Q 2025 such that it is sort of a neutral impact?

I would be curious if you could provide any color on the actual dosage share and debt clinics particularly among new puppies, did you retain or cede some share?

I specifically wanted to ask about the dermatology franchise and how you're thinking about your positioning in 2025 from a pricing versus mix standpoint